# Pediatric Zylet Safety and Efficacy Study

> **NCT00420628** · PHASE4 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 108 (actual)

## Conditions studied

- Chalazion
- Hordeolum

## Interventions

- **DRUG:** loteprednol etabonate/tobramycin opthalmic suspension
- **DRUG:** vehicle

## Key facts

- **NCT ID:** NCT00420628
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-01
- **Final completion:** 2009-06
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2011-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420628, "Pediatric Zylet Safety and Efficacy Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00420628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*